Close

MHRA Grants Rentschler Biopharma cGMP Compliance Certificate

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

After undergoing an inspection by the UK Medicines & Healthcare Products Regulatory Agency (MHRA), Rentschler Biopharma SE’s UK facility for advanced therapy medicinal products (ATMP) has been granted a Manufacturing Compliance Certificate in accordance with current good manufacturing practice (cGMP). This certification signifies that the contract development and manufacturing organization (CDMO) located within the Cell and Gene Therapy Catapult’s Manufacturing Innovation Centre in Stevenage is fully compliant and authorized to produce adeno-associated virus (AAV) vectors for gene therapy.

With the successful completion of the MHRA inspection, the CDMO is now equipped to provide its complete array of services for the clinical supply of AAV. This includes services ranging from bioprocess and analytical development to cGMP manufacturing.

Dr. Robert Panting, General Manager of Rentschler Biopharma’s ATMP business, expressed the significance of MHRA’s approval, considering it a pivotal achievement for Rentschler Biopharma.

In a related development, Rentschler Biopharma recently entered into a collaboration with CGT Catapult aimed at enhancing the efficiency and processes involved in gene therapy AAV production. This two-year initiative is expected to leverage automated and digital process analytical technologies (PAT). Dr. Christian Schetter, Chief Scientific Officer of Rentschler Biopharma, stated that this project’s ultimate goal is to mitigate risks associated with the transition from early-stage to late-stage manufacturing. The project is financially supported by Innovate UK through a grant focused on the digitalization and automation of medicines research and development and manufacturing.

Latest stories

Related stories

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Pharma Support Powers Sofinnova Biotech Acceleration Fund

Sofinnova Partners Closes €165M Biotech Acceleration Fund with Strong...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back